<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03902613</url>
  </required_header>
  <id_info>
    <org_study_id>7673</org_study_id>
    <nct_id>NCT03902613</nct_id>
  </id_info>
  <brief_title>18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder</brief_title>
  <official_title>18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this project is to understand what causes bipolar disorder and how medications
      treat bipolar depression. Particularly, the project focuses on the importance of dopamine
      signaling in the process. Participants will have two different brain scans (MRI and PET
      scan). They will also have treatment for your depression with an FDA approved medication,
      lurasidone (Latuda). The study is funded by the Columbia University Irving Institute to
      improve the treatment of bipolar disorder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 7, 2019</start_date>
  <completion_date type="Actual">August 1, 2019</completion_date>
  <primary_completion_date type="Actual">August 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>15 minutes</time_frame>
    <description>Measures severity of depression symptoms; Scale from 0 to 54 with higher values associated with greater depression severity</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>Lurasidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label treatment with lurasidone within the dose range of 20-60 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lurasidone</intervention_name>
    <description>Participant will have an open label trial of lurasidone for eight weeks.</description>
    <arm_group_label>Lurasidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bipolar I disorder, bipolar II disorder or other specified bipolar disorder

          -  Currently in a major depressive episode and moderately depressed

          -  Age 18-50 years old

          -  Patients on psychiatric medications will not be benefitting from those medications

          -  Females of childbearing potential must be willing to use an acceptable form of birth
             control throughout the study

        Exclusion Criteria:

          -  Diagnosis of schizophrenia or other psychotic disorders, recent alcohol or substance
             use disorder, recent anorexia or bulimia nervosa

          -  Previous failed trial of lurasidone, or had intolerable side effects of lurasidone

          -  Significant active physical illness

          -  Actively suicidal

          -  ECT within the past 6 months

          -  Recent pregnancy, abortion or miscarriage or plans to conceive during the study;
             currently lactating

          -  Metal in the body that is not MRI compatible

          -  Current, past or anticipated exposure to radiation

          -  Currently taking an anticoagulant medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Lan, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Martin Lan</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry at CUMC</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

